Funding round brings in $20M for Alzheimer's drug developer

05/24/2013 | MedCityNews.com

Acumen Pharmaceuticals has pulled in $20 million in a Series A funding round from BVF Partners, NeuroVentures Fund and other investors. Proceeds will go toward preclinical development of the firm's Alzheimer's disease drug candidate, an antibody that targets soluble oligomers of the amyloid beta peptide in the brain.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN